FORTIBONE
Description
Due to the increase in human lifespan, osteopenia and osteoporosis have progressively turned into a major worldwide public health problem. It is expected that by 2025 the economic costs will be more than EUR 45 billion in the European Union and approx. USD 25 billion in the United States. In discussions with medical doctors, we learned that there is huge dissatisfaction with existing treatment options for osteoporosis as most medications have an anti-catabolic effect and so can cause side-effects. In comparison to existing medications, FORTIBONE® has a signaling effect on osteoblasts to counterbalance the collagen degradation in the extracellular bone matrix, which is the essential framework for bone mineralization. The result is a considerably higher synthesis of collagenous bone matrix. The published clinical study from 2018 showed a significant increase in bone mineral density of 5–7 % in the spine and the femoral neck.